NCT07132242View on ClinicalTrials.gov

SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

August 30, 2025

Primary Completion Date

August 30, 2028

Study Completion Date

December 31, 2028

Conditions
Metastatic Breast Cancer With HER2 Positive
Interventions
DRUG

SHR-A1811 4.0mg/kg

SHR-A1811 4.0mg/kg, IV, Day 1, Q3W

DRUG

Pyrotinib 240mg

Pyrotinib 240mg, po, QD, from Day 8 to Day 21,Q3W

DRUG

SHR-A1811 4.8mg/kg

SHR-A1811 4.8mg/kg, IV, D1, Q3W

DRUG

Pyrotinib 320mg

Pyrotinib 320mg, po, QD, from Day 8 to Day 21, Q3W

All Listed Sponsors
collaborator

Yunnan Cancer Hospital

OTHER

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER